An exploratory, double-blind, placebo controlled, 2 period cross-over, 3 cohort, single center, pharmacodynamic study to assess the effect of AZD6140 on respiratory parameters in healthy subjects, mild asthmatics and COPD patients age 40 to 70 years.

Study identifier:D5130C00028

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An exploratory, double-blind, placebo controlled, 2 period cross-over, 3 cohort, single center, pharmacodynamic study to assess the effect of AZD6140 on respiratory parameters in healthy subjects, mild asthmatics and COPD patients age 40 to 70 years.

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 2005
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria